Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and last look at today. Sign up for free to receive it directly in your inbox. Here’s what CNBC TV’s producers were watching on Wednesday and what’s on the radar for Thursday’s session. The Dow It closed above 48,000 for the first time ever , settling in at 48,255. It also hit another new high. The Dow is now up nearly 3% in three days. Goldman Sachs is up 6.7% in those three days. Merck is up 6% in three days. Disney is up 5.3% in three days. “Worldwide Exchange,” starting at 5 a.m. ET, will focus in on the big caps of the Dow. Don’t miss it. .DJI YTD mountain The Dow Jones Industrial Average year to date M-I-C-K-E-Y… Disney reports first thing Thursday morning on “Squawk Box” with Becky Quick, Andrew Ross Sorkin and Joe Kernen. CFO Hugh Johnston will join the “Squawk” team along with Julia Boorstin, who covers the stock. Disney shares are up 2.6% in the three months since the company last reported. Shares are nearly 7% from the June 30 52-week high. In the last year, the stock is up 15.5%, and it’s has gained 4.8% year to date. It ranks 21st in the Dow 30’s 2025 performance. DIS YTD mountain Walt Disney shares year to date The airlines As the House gets set to vote on a bill to reopen the government, it’ll still take a bit of time to get things up and running. Over the last 42 days, here’s how the airlines have fared. United Airlines is up 3.6% since the government shuttered. Delta is up 6.6% over the same period. American Airlines is up 20% during the shutdown. JetBlue fell 11% during this time. Southwest is up nearly 5% since the shutdown started. Alaska Air is down 13% since Oct. 1. Luxury JPMorgan hosts a conference on luxury stocks on Thursday … in Paris, of course. Hermes is 25% off its Valentine’s Day high. The stock is up 5% in three days. Richemont , the name behind brands like Cartier, hit a high on Tuesday. The stock is up 6.6% in three days and up 27% in three months. Kering is 11% from its October high. Shares are up 7% in five days. They own Gucci and Saint Laurent. LVMH is 5% from its January high. The stock is up 7% in three days. Burberry reports early in the morning. That stock is 10% from its July high. The stock is up 9% in three days. Prada — as in the Will Smith song that goes: “you gotta Prada bag with a lot stuff in it” — is 31% from its Feb. 14 high. The stock is up 9% in three days.
Category: 3. Business
-

China ready to deepen mutually beneficial cooperation with Guinea: vice premier
Chinese Vice Premier Liu Guozhong, also a member of the Political Bureau of the Communist Party of China (CPC) Central Committee, meets with Guinean President Mamadi Doumbouya at the presidential office in Conakry, Guinea, Nov. 11, 2025. Liu visited the West African country from Monday to Wednesday. He also attended the inauguration of the Simandou iron ore mine project as President Xi Jinping’s special representative. [Photo/Xinhua]
CONAKRY, Nov. 12 — China stands ready to build on its long-standing friendship with Guinea, enhance mutual support, and deepen mutually beneficial cooperation between the two countries, Chinese Vice Premier Liu Guozhong has said.
Liu, also a member of the Political Bureau of the Communist Party of China (CPC) Central Committee, made the remarks during a visit to the West African country from Monday to Wednesday at the latter’s invitation. He also attended the inauguration of the Simandou iron ore mine project as President Xi Jinping’s special representative.
During his visit, Liu met with Guinean President Mamadi Doumbouya. The two sides held in-depth discussions on China-Guinea relations and cooperation across various fields.
Conveying Xi’s cordial greetings to Doumbouya, Liu commended Guinea’s progress in economic and social development and extended warm congratulations on the rapid and efficient completion of the Simandou project.
Liu underlined the project as a fruit of nearly 70 years of friendship and cooperation between China and Guinea, as well as between China and Africa, noting that it will play a vital role in advancing Guinea’s economic development and the implementation of its Simandou 2040 strategic plan.
During the Beijing Summit of the Forum on China-Africa Cooperation (FOCAC) last year, Xi had a successful meeting with Doumbouya, which charted the course for the future development of bilateral relations, said the Chinese vice premier.
Noting that the fourth plenary session of the 20th CPC Central Committee has drawn up a blueprint for China’s development over the next five years, Liu said that China is willing to build on its long-standing friendship with Guinea, enhance mutual support, deepen mutually beneficial cooperation, fully implement the outcomes of the FOCAC Beijing Summit, and join hands to advance modernization.
Doumbouya asked Liu to extend his sincere greetings to Xi.
Guinea views its relations with China from a strategic perspective, cherishes the traditional friendship between the two countries, welcomes more Chinese enterprises to invest in Guinea, and will create favorable conditions for the two sides to expand cooperation across multiple fields, he said.
Doumbouya also expressed Guinea’s willingness to enhance international cooperation with China and work together to safeguard their sovereignty, security, and development interests.
Liu also attended the signing and unveiling ceremony of the China-Africa Joint Medical Center in Guinea.

Chinese Vice Premier Liu Guozhong, also a member of the Political Bureau of the Communist Party of China (CPC) Central Committee, attends the signing and unveiling ceremony of the China-Africa Joint Medical Center in Guinea, Nov. 12, 2025. Liu visited the West African country from Monday to Wednesday. He also attended the inauguration of the Simandou iron ore mine project as President Xi Jinping’s special representative. [Photo/Xinhua]
Continue Reading
-

US ‘disappointed’ that Rolls-Royce will build UK’s first small modular reactors | Nuclear power
Keir Starmer has announced that the UK’s first small modular nuclear reactors will be built in north Wales – but immediately faced a backlash from Donald Trump’s administration after it pushed for a US manufacturer to be chosen.
Wylfa on the island of Anglesey, or Ynys Môn, will be home to three small modular reactors (SMRs) to be built by British manufacturer Rolls-Royce SMR. The government said it will invest £2.5bn.
SMRs are a new – and untested – technology aiming to produce nuclear power stations in factories to drive down costs and speed up installation. Rolls-Royce plans to build reactors, each capable of generating 470 megawatts of power, mainly in Derby.
The government also said that its Great British Energy – Nuclear (GBE-N) will report on potential sites for further larger reactors. They would follow the 3.2GW reactors under construction by French state-owned EDF at Hinkley Point C in Somerset and Sizewell C in Suffolk.
The Labour government under Starmer has embraced nuclear energy in the hope that it can generate electricity without carbon dioxide emissions, while also providing the opportunity for a large new export industry in SMRs.
However, it faced the prospect of a row with the US, piqued that its ally had overlooked the US’s Westinghouse Electric Company when choosing the manufacturer for the Wylfa reactors.
Ahead of the publication of the UK announcement, US ambassador Warren Stephens published a statement saying Britain should choose “a different path” in Wales.
“We are extremely disappointed by this decision, not least because there are cheaper, faster and already-approved options to provide clean, safe energy at this same location,” he said.
The Trump administration last month signed an $80bn (£61bn) deal with Westinghouse, which had been struggling financially, to build several of the same larger reactors proposed at Wylfa. Under the terms of that deal, the Trump administration could end up taking a stake in the company.
A source close to the UK government said: “This is the right choice for Britain. This is our flagship SMR programme, producing homegrown clean power with a British company and we have chosen the best site for it.”
While the ambassador’s intervention is unlikely to change the future of Wylfa, it may put pressure on the UK to choose Westinghouse if it does go ahead with future large reactors.
It is understood that Torness, to the east of Edinburgh, and Hunterston, to the west of Glasgow, would be considered for future large reactors. A source close to the energy secretary, Ed Miliband, said the government wants to generate nuclear power in Scotland, despite the opposition of the ruling Scottish National party.
Wylfa generated nuclear power from 1971 until 2015, when its last reactor was shut down. Japan’s Hitachi tried to build a new plant there, but these efforts collapsed in 2019 after it failed to agree funding with the government. GBE-N bought the site from Hitachi.
Starmer said: “Britain was once a world leader in nuclear power, but years of neglect and inertia has meant places like Anglesey have been let down and left behind.
“This government isn’t just reversing decline, it’s delivering thousands of future-proofed jobs, driving billions in investment and providing cheaper energy bills in the long term.”
However, Sharon Graham, general secretary of Unite, said that building three smaller reactors rather than one larger one at Wylfa would be a mistake because it would not maximise the number of jobs for British workers. The union represents some workers in the nuclear industry.
“Failure to support a gigawatt nuclear power station at Wylfa would be a huge missed opportunity in securing the UK’s energy security,” she said.
Nevertheless, the confirmation of a UK site will be another welcome step for Rolls-Royce, the FTSE 100 maker of jet engines that was chosen as the government’s preferred developer in June.
It owns the majority of Rolls-Royce SMR, alongside Qatar’s sovereign wealth fund, France’s BNF Resources, US energy company Constellation, and the Czech utility CEZ, which could order as many as six of the reactors.
Rolls-Royce SMR has more than 1,000 employees, who are racing to produce technology that will also be installed at Temelín in the Czech Republic.
Tom Greatrex, chief executive of the Nuclear Industry Association, a lobby group, said the Wylfa project was “an exciting opportunity for a UK technology, our domestic supply chain and skilled workforce”.
He added: “To achieve the amount of nuclear capacity the country needs for a secure, reliable and price-predictable electricity mix, we will need reactors large and small.
“There will be other projects using different reactor technologies, and potentially further gigawatt-scale plants beyond Sizewell C. Partnership with like-minded allies, including the US, will be a part of delivering that ambition.”
Continue Reading
-
Global energy body’s fossil fuel backpedal – Politico
- Global energy body’s fossil fuel backpedal Politico
- World Energy Outlook 2025 – Analysis IEA – International Energy Agency
- Supply boom in cheaper renewables will seal end of fossil fuel era, says IEA The Guardian
- World oil and gas demand could grow until 2050, IEA says Reuters
- Economic and demographic trends to create opportunities for solar as world becomes ‘thirsty for energy’ PV Tech
Continue Reading
-

Nikkei 225, Hang Seng Index
View of the Skytree from Ueno and Asakusa in Tokyo
Jackal Pan | Moment | Getty Images
Asia-Pacific markets mostly rose Thursday, following mixed trading on Wall Street as investors kept an eye on the U.S. government, which appeared poised to reopen as soon as the end of the week.
Japan’s benchmark Nikkei 225 index rose 0.23% in early trading, while the Topix added 0.62% to hit a record high.
South Korea’s Kospi rose 1.07%, while the small-cap Kosdaq jumped 2.52%.
Australia’s S&P/ASX 200 was down 0.25%.
Futures for Hong Kong’s Hang Seng Index pointed to a lower open, trading at 26,899, against the index’s previous close of 26,922.73.
U.S. equity futures ticked lower in early Asian hours after a continued market rotation powered the Dow Jones Industrial Average to record its first close above 48,000 Wednesday stateside.
Overnight, the 30-stock Dow closed up 326.86 points, or 0.68%, at 48,254.82. The index also hit a fresh all-time intraday high in the session. The S&P 500 traded around the flatline, settling up 0.06% at 6,850.92, while the Nasdaq Composite dropped 0.26% to finish at 23,406.46.
— CNBC’s Sean Conlon and Pia Singh contributed to this report.
Continue Reading
-
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development USA – English APAC – English APAC – Traditional Chinese
– Using Ascletis’ proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human primate studies.
– ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study.
– Co-formulation of ASC36 and ASC35 demonstrated approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in a head-to-head DIO rat study.
– Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.
– Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for co-formulation of ASC36 and ASC35 is expected in the second quarter of 2026.
– The Company will host a conference call in Mandarin at 10:00 a.m. China Standard Time on November 13, 2025.
HONG KONG, Nov. 12, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces the co-formulation of ASC36, a once-monthly next-generation amylin receptor agonist and ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for co-formulation of ASC36 and ASC35 for the treatment of obesity in the second quarter of 2026.
Both ASC36, a once-monthly next-generation amylin receptor agonist, and ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist, were discovered and developed in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. Ascletis has successfully co-formulated ASC36 and ASC35 in the proprietary ultra-long-acting formulation to enable once monthly subcutaneous (SQ) administration using its ULAP technology. Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH. Some of amylin receptor peptide agonists aggregate or precipitate at neutral pH, which leads to loss of potency, turbidity/particles, device clogging, and higher immunogenicity risk.
In head-to-head non-human primate (NHP) studies, co-formulation of ASC36 and ASC35 demonstrated a comparable pharmacokinetic profile to ASC36 and ASC35 dosed alone, supporting once-monthly SQ dosing.
ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study. ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study (press release). The co-formulation of ASC36 and ASC35 demonstrated approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in a head-to-head DIO rat study (Table 1).
Table 1. ASC36 monotherapy and co-formulation of ASC36 and ASC35 demonstrated statistically and significantly more weight loss than eloralintide monotherapy and the co-formulation of eloralintide and tirzepatide in DIO rats after 7-day treatment
Group
Dosing
Total body weight change
from baselineGreater relative weight
loss versus eloralintide
monotherapy or co-
formulation of eloralintide
and tirzepatideObese rats treated
with vehicleVehicle,
SQ, Q2D
-0.5 %
–
Obese rats treated
with ASC36
monotherapy5 nmol/kg,
SQ, Q2D
-9.6%
(p =0.028 vs eloralintide
monotherapy)32%
(vs eloralintide
monotherapy)Obese rats treated
with eloralintide
monotherapy5 nmol/kg,
SQ, Q2D
-7.3 %
–
Obese rats treated
with co-formulation
of ASC36 and
ASC355 nmol/kg
ASC36/8
nmol/kg ASC35,SQ, Q2D
-14.5%
(p <0.0001 vs eloralintide
monotherapy; p <0.0001
vs co-formulation of
eloralintide and
tirzepatide)99%
(vs eloralintide
monotherapy)51%
(vs co-formulation of
eloralintide and
tirzepatide)Obese rats treated
with co-formulation
of eloralintide and
tirzepatide5 nmol/kg
eloralintide/8
nmol/kg
tirzepatide,SQ, Q2D
-9.6 %
–
Note: DIO rats/obese rats: diet-induced obese rats; SQ: subcutaneous; Q2D: once every two days.
“Based on these encouraging preclinical data, we believe the co-formulation of ASC36 and ASC35 has the potential to lead to greater weight loss reduction in people with obesity than single-agent therapies can achieve alone,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “The growing body of evidence reinforces our platform technologies’ ability to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides.”
Monotherapy and Co-formulation Therapies with ASC36
Ascletis is developing ASC36 as the cornerstone of its once-monthly therapies for the treatment of cardio-metabolic diseases including obesity. With the potential for better efficacy and improved tolerability to GLP-1 therapies, ASC36 is an ideal drug candidate to develop as a monotherapy and co-formulations with other long-acting agents such as ASC35 and potentially ASC47, an adipose-targeted thyroid hormone receptor beta (THRβ) agonist.
Ascletis’ AISBDD and ULAP technologies enable the Company to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides, including ASC35 and ASC36. Based on the properties of peptides, the Company can design, through its proprietary ULAP technology, various slow-release constants (k) for peptides in SQ depots to precisely release injected peptides over desired dosing intervals to reduce peak-to-trough ratios and improve clinical outcomes.
Conference Call
Ascletis will host a conference call in Mandarin at 10:00 a.m. China Standard Time on November 13, 2025. A live webcast of the call will be available via Tencent Meeting/ VooV Meeting, with the Meeting ID: 573-120-481, or access links of:
Chinese Mainland: https://meeting.tencent.com/dm/uIyhG5Mtu3op; or
International: https://voovmeeting.com/dm/uIyhG5Mtu3op.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
For more information, please visit www.ascletis.com.
Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
[email protected]Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
[email protected]
[email protected]SOURCE Ascletis Pharma Inc.

Continue Reading
-

US Stock Futures Edge Lower, Oil Extends Losses: Markets Wrap
(Bloomberg) — US equity-index futures edged lower and Asian markets opened on a subdued note after a lackluster Wall Street session, as investors stayed cautious with limited economic data clouding the outlook for Federal Reserve policy.
Contracts for the S&P 500 and the Nasdaq 100 index retreated 0.2%, after the underlying gauges were largely unchanged Wednesday. However, Bloomberg’s gauge for the Magnificent Seven fell 1.2%, extending declines for a second straight session. Treasuries steadied in early trading Thursday after yields fell across the curve.
The moves were more pronounced in the commodities market as gold and copper advanced on Fed rate-cut bets. Oil extended its drop after slumping by the most since June as a key market gauge flashed weakness and OPEC said global crude supplies surpassed demand sooner than anticipated.
Investor focus is on the yen after Japanese Finance Minister Satsuki Katayama issued a fresh warning on currency movements. The yen weakened to the key threshold of 155 per dollar on Wednesday, inching closer to levels where authorities last intervened in markets.
With US earnings season nearing completion, markets are shifting focus to the Fed and the outlook for potential interest-rate cuts. The absence of key indicators — such as unemployment figures and October’s consumer price index — has fueled uncertainty around monetary policy, with the White House confirming those reports are unlikely to be released due to the shutdown.
“While the markets are pricing the end of the government shutdown, there is an even bigger mountain ahead of us, and that is the resumption of all of the economic data that we have missed,” said Michael Landsberg at Landsberg Bennett Private Wealth Management. “As the fog lifts, we will see if market positioning has been correct and it is still clear sailing or if there is a big repricing necessary.”
The S&P 500 edged up 0.1%, lifted in part by a 9% surge in Advanced Micro Devices Inc. shares. The Nvidia Corp. rival in AI chips projected accelerating sales growth over the next five years, fueled by robust demand for its data center products. Meanwhile, the tech-heavy Nasdaq 100 slipped 0.1%, paring an earlier decline of 0.6%.
There is “probably some profit taking after strong gains on Monday and ahead of Nvidia earnings next week, especially since recent tech earnings have not been enough to satisfy the bulls,” said Sameer Samana, head of global equities and real assets at Wells Fargo Investment Institute. “Also, there’s probably an element of ‘selling the news’ of the shutdown ending.”
Investors are also paying attention to the progress in ending the longest ever US government shutdown.
House Speaker Mike Johnson said he believes the legislation, a hard-fought compromise forged in the Senate and blessed by President Donald Trump, will pass quickly. But he’ll have to keep his fractious party in line in the face of stiff opposition from House Democrats whose leaders are urging them to vote against the legislation.
With the government shutdown delaying key economic data, the real challenge isn’t the short-term drag on growth — it’s the increasing difficulty for investors and the Fed to gauge the economic outlook, noted Seema Shah at Principal Asset Management.
“As data releases resume, the case for a Fed rate cut in December should re-emerge, reinforcing a risk-on backdrop,” she said. “This environment favors US equities, particularly big tech and cyclicals poised to benefit from a more accommodative Fed stance.”
Still, Boston Fed President Susan Collins said she favored holding rates steady amid still-strong growth that could slow or stall progress on cooling inflation.
Treasuries rallied Wednesday, with the 10-year yield closing five basis points lower at 4.07%, fueled by expectations the Fed will cut interest rates in December. Bond traders were also piling into Treasury options, targeting a drop in the 10-year yield below 4% in coming weeks.
Corporate News:
Cisco Systems Inc. shares gained in late trading after the network-equipment giant boosted its 2026 forecast, showing progress in its effort to capture more artificial intelligence spending. Toyota Motor Corp. confirmed it will plow as much as $10 billion into the US over the next five years to boost its local operations. Anthropic PBC plans to spend $50 billion to build custom data centers for artificial intelligence work in several US locations, including Texas and New York, the latest expensive pledge for infrastructure to support the AI boom. Volkswagen AG and Rivian Automotive Inc. have ambitions of selling the electric vehicle technology they’re developing together to other carmakers in the future. Some of the main moves in markets:
Stocks
S&P 500 futures fell 0.1% as of 9:26 a.m. Tokyo time Hang Seng futures fell 0.3% Japan’s Topix rose 0.6% Australia’s S&P/ASX 200 fell 0.2% Euro Stoxx 50 futures rose 0.1% Currencies
The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1589 The Japanese yen was little changed at 154.77 per dollar The offshore yuan was little changed at 7.1116 per dollar The Australian dollar was little changed at $0.6535 Cryptocurrencies
Bitcoin fell 0.4% to $101,494.07 Ether fell 0.5% to $3,406.57 Bonds
The yield on 10-year Treasuries advanced one basis point to 4.08% Japan’s 10-year yield was unchanged at 1.685% Australia’s 10-year yield declined one basis point to 4.37% Commodities
West Texas Intermediate crude fell 0.3% to $58.31 a barrel Spot gold was little changed This story was produced with the assistance of Bloomberg Automation.
©2025 Bloomberg L.P.
Continue Reading
-

Banco do Brasil cuts 2025 net income outlook as farmer defaults surge
SAO PAULO, Nov 12 (Reuters) – Brazilian state-run lender Banco do Brasil (BBAS3.SA) on Wednesday lowered its outlook for adjusted net income this year, citing higher funding expenses and rising defaults among local farmers.The bank now expects annual net income of
18 billion t
o
21 billion reais ($3.33 billion-$3.89 billion), down from a previous forecast of 21-25 billion reais.Sign up here.
Banco do Brasil, long seen as a pillar of farm credit in the country, has been grappling with record default levels in its agribusiness portfolio, which hit results and raised investor concern over its exposure to the sector.In the third quarter, the bank’s agribusiness default ratio hit 5.34%, up from 3.49% in the prior three-month period and above its overall 90-day default ratio of 4.93%, which rose 72 basis points sequentially.
“Given this scenario, we have acted with transparency and implemented effective measures to address the situation, responding quickly and decisively,” the bank said in its earnings report.
Banco do Brasil posted an adjusted net profit of 3.79 billion reais ($701.35 million) for the third quarter, down 60.2% from a year earlier but slightly above the 3.71 billion reais expected by analysts polled by LSEG.
The lender’s return on equity, a gauge of profitability, was down 1,276 basis points year-on-year to 8.4%, but unchanged quarter-over-quarter.
In another revision, Banco do Brasil also raised its estimate for cost of credit in 2025 to a range between 59 billion and 62 billion reais, from the 53 billion to 56 billion reais forecast before.
($1 = 5.4039 reais)
Reporting by Fernando Cardoso; Editing by Gabriel Araujo
Our Standards: The Thomson Reuters Trust Principles.
Continue Reading
-

IMF Staff Completes Post-Financing Assessment Mission to Uganda
Washington, DC: An IMF staff team led by Jesmin Rahman visited Kampala from November 3 to 7 to conduct Uganda’s post-financing assessment (PFA).[1]
Economic growth was broad-based, reaching 6.3 percent in FY2024/25. Inflation remains stable and below the 5 percent medium-term target of the Bank of Uganda (BoU). Gross international reserves strengthened, supported by higher exports, capital inflows, and stepped-up foreign exchange purchases by the BoU.
The fiscal position deteriorated significantly in FY2024/25 due to higher current spending, including one-off items. Macroeconomic conditions are expected to remain favorable in the near term, with further improvement anticipated once oil production begins in FY2026/27. However, the outlook is subject to downside risks, including global trade and financial uncertainties as well as fiscal policy slippages.
The staff team assessed Uganda’s capacity to repay the IMF as adequate under a combination of external and domestic shocks. The IMF team thanks the authorities for their productive engagement and hospitality.
The IMF Executive Board is expected to consider Uganda’s PFA in January 2026.
[1] A Post Financing Assessment (PFA) is expected for countries with outstanding credit above the absolute or quota-based thresholds that do not have an IMF-supported program or a staff-monitored program. It reports on the member’s policies, the consistency of the macroeconomic framework with the objective of medium-term viability, and the implications for the member’s capacity to repay the Fund. PFA Factsheet.
Continue Reading
-
Equities rise modestly, US bond yields dip with government reopen, interest rates in focus – Reuters
- Equities rise modestly, US bond yields dip with government reopen, interest rates in focus Reuters
- Dow Jones E-Commerce Giant Amazon, Tesla Stock In Or Near Buy Zones Investor’s Business Daily
- S&P 500 nears 6,900 as Wall Street rally extends on easing political risk and tech strength Traders Union
- Stocks and Bonds Climb as US Economic Data Fuels Rate-Cut Hopes TradeAlgo
- S&P 500 Futures Rise in Premarket Trading; On Holding, CAE Inc Lead Barron’s
Continue Reading
